My lab aims to understand the basic mechanisms controlling DNA replication in mammalian cells and how disruption of this process leads to genomic instability and cancer.
My research focuses on improving the response to therapy in ovarian cancer and other gynaecological cancers. The key aims are to understand the immune effects of chemotherapy and identify targets to enhance anti-tumor effects and overcome therapy resistance. The ultimate goal is to take these findings forward to clinical trials and develop better treatment approaches for cancer patients to prolong survival and reduce the risk of relapse.
My main research interests are in haematopoietic stem cells (HSCs) and leukemic initiating cells. I seek to understand how intrinsic and extrinsic signals are integrated by normal and malignant stem cells.
I am interested in unveiling and modelling the mechanisms that drive clonal haematopoiesis and exploring niche-based therapies to prevent it, as clonal haematopoiesis has been recently linked to an increase in the development of leukaemia and cardiovascular conditions.
My research is focused on investigating how the epitranscriptome regulates normal and malignant haematopoiesis.
Our research is focused in defining the cellular interactome of haematopoietic stem cells and leukaemic stem cells inside their niches during adulthood, ageing and disease. We are also interested in the cellular and molecular mechanisms that drive clonal selection and evolution in clonal haematopoiesis.
My research focusses on understanding cancer-specific metabolism in acute myeloid leukaemia and targeting this metabolism to overcome therapeutic resistance. I also explore the role of diet and obesity in leukaemogenesis and response to therapy.